Clinical Trial Update: Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children [Phase 3]

View source ↗

Summary

A multicenter Phase 3 trial evaluating sublingual grass pollen allergen extract for children with allergic rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis

Drugs mentioned

• Grass pollen allergen extract sublingual immunotherapy (grass pollen allergen extract)

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Allergic Rhinoconjunctivitis | Phase 3 | Status: COMPLETED